4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• 4D Molecular Therapeutics, Inc. has received a consensus rating of "Moderate Buy" from analysts, with the average 12-month target price set at $30.40.
• The company reported (-$0.98) earnings per share, missing analysts' expectations, and had a negative net margin of 594,375.81% in its latest earnings report.
• Institutional investors own 99.27% of the company's stock, indicating strong institutional interest in 4D Molecular Therapeutics.

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the eleven brokerages that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $30.40.

Several research firms have commented on FDMT. The Goldman Sachs Group cut their price objective on 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. Weiss Ratings reissued a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research report on Tuesday, July 29th. Barclays cut their price objective on 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating on the stock in a research report on Friday, May 9th. Chardan Capital reissued a "buy" rating and issued a $25.00 price objective on shares of 4D Molecular Therapeutics in a research report on Tuesday. Finally, Roth Capital cut their price objective on 4D Molecular Therapeutics from $44.00 to $38.00 and set a "buy" rating on the stock in a research report on Tuesday.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of 4D Molecular Therapeutics in the fourth quarter worth about $50,000. Velan Capital Investment Management LP acquired a new position in shares of 4D Molecular Therapeutics in the fourth quarter worth about $56,000. Virtus ETF Advisers LLC lifted its stake in shares of 4D Molecular Therapeutics by 173.9% in the fourth quarter. Virtus ETF Advisers LLC now owns 10,333 shares of the company's stock worth $58,000 after acquiring an additional 6,560 shares in the last quarter. Quadrature Capital Ltd acquired a new position in shares of 4D Molecular Therapeutics in the second quarter worth about $42,000. Finally, Los Angeles Capital Management LLC bought a new stake in 4D Molecular Therapeutics in the second quarter valued at about $42,000. Institutional investors and hedge funds own 99.27% of the company's stock.

4D Molecular Therapeutics Trading Up 8.5%

Shares of 4D Molecular Therapeutics stock opened at $6.67 on Thursday. 4D Molecular Therapeutics has a twelve month low of $2.23 and a twelve month high of $17.41. The stock has a market capitalization of $308.99 million, a P/E ratio of -1.89 and a beta of 2.83. The business's fifty day moving average price is $4.56 and its 200 day moving average price is $4.11.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last issued its earnings results on Monday, August 11th. The company reported ($0.98) earnings per share for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.10). 4D Molecular Therapeutics had a negative net margin of 594,375.81% and a negative return on equity of 40.15%. The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.52 million. As a group, sell-side analysts predict that 4D Molecular Therapeutics will post -2.84 EPS for the current year.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.